Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06765863

LIFT-UP: Randomized Controlled Trial of Fortification of Human Milk

The goal of the LIFT-UP randomized controlled trial is to evaluate the efficacy of feeding routinely and fortified human milk using a standardized clinical protocol to very low birthweight (VLBW) or very preterm (VPT) infants in the NICU compared to not feeding routinely fortified human milk using the standardized clinical protocol.

The primary research question is: Will VLBW or VPT infants in the NICU who are fed fortified human milk using a standardized feeding protocol have better growth outcomes by facility discharge and at 3 months of age, less illness by discharge, and decreased mortality by discharge and at one month compared to those who are not routinely fed fortified human milk using the same feeding protocol?

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 48 hour

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ballari Medical College and Research Centre, Ballary, Karnataka, India

Loading trial locations.

About this study

AIM: To improve feeding and growth outcomes among very low birthweight (LBW; ≤1.5kg) or very preterm (≤32 weeks gestational age) infants admitted to neonatal intensive care units (NICU) in India through fortification of human milk.

OBJECTIVE: To evaluate (via individually randomized controlled study) the efficacy of feeding routinely and fortified human milk using a standardized clinical protocol to very LBW or very preterm infants in the NICU compared to not feeding routinely fortified human milk using the standardized clinical protocol.

STUDY DESIGN This study is a multi-site individually randomized prospective trial among VLBW or VPT infants admitted to the NICU in study facilities who consume human milk and meet eligibility criteria (along with their mothers).

SCREENING AND ENROLLMENT All infants admitted to the NICU and their mothers will be screened for study eligibility. Screening will be performed within 24 hours of birth for inborn infants and within 48 hours of birth for outborn infants. Eligible dyads with the intention to feed human milk [mother's own milk (MOM) or pasteurized donor human milk (PDHM)] whose mothers provide consent will be enrolled into the study.

Once the mother-infant dyad is enrolled and prior to randomization, they will:

Receive the guideline-driven standard of care and be provided access to breast pumps to help initiate and advance breast milk feeding. The guideline-driven standard of care includes facility-based lactation support/feeding counseling + KMC + WASH components designed specifically for small vulnerable newborns and was developed as part of a different study protocol (see NCT06390943).

Adhere to a clinical guideline including targets for initiating and advancing breast milk feeding. Initially, this clinical guideline will help infants achieve breast milk volume intake of at least 60 mL/kg/day, the primary criterion for randomization. After randomization, the clinical guideline will continue to support advancing human milk feeding for all infants advance to 180 mL/kg/day.

RANDOMIZATION Once an infant consumes at least 60 mL/kg/day of breast milk, enrolled dyads will be assessed for eligibility for randomization. Eligible dyads will be randomized individually in a 1:1 ratio to either the intervention or comparison arm. Randomization sequences will be previously generated by the study statistician. If an infant does not consume at least 60 mL/kg/day of breastmilk by day 10 of chronological age, the mother-infant dyad will be administratively withdrawn from the study.

DELIVERY OF INTERVENTION Mothers of infants randomized to the intervention arm will express their breast milk into a standardized measurement cup (or PDHM can be used). Clinical research staff will mix human milk fortifier (HMF) in human milk (either MOM or PDHM, if available) per manufacturer specifications per feed for a minimum of 21 days.

Dyads in both arms will continue to receive the guideline-driven standard of care, access to breast pumps, and follow the volume target and trajectory protocol until they meet stopping criteria. Data will be collected every 24 hours, including a log at every feed, regardless of study arm assignment.

If an infant in either arm does not meet protocolized minimum volume targets or trajectories AND that infant meets weight-based safety net criteria, clinicians will intervene per judgment aligned with national and local protocols.

The intervention will not be continued once the infant meets stopping criteria with the goal of the infant having fully transitioned to exclusive breast milk feeding by then.

STOPPING CRITERIA After the minimum duration of 21 days post-randomization, hospitalized infants should continue to receive volume targeted feeding with or without HMF for as long as they receive expressed breast milk. Once infants transition to full, direct breastfeeding in preparation for discharge or are being discharged per clinician discretion, they will stop adhering to the volume targets and infants in the intervention group will stop receiving fortified human milk.

DISCHARGE FROM FACILITY TO HOME After stopping criteria are met, routine clinical care around infant feeding will be provided. Infants can be discharged home when deemed clinically appropriate per facility protocols and clinician judgment. The guideline-driven standard of care will encourage all mothers to exclusively breastfeed their infants prior to discharge and to continue doing so after discharge.

POST-DISCHARGE FACILITY VISITS All dyads will be followed up at 2 weeks of age, 4 weeks of age, and 3 months of chronological age.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Very LBW (≤1.5kg)* or very preterm (≤32 weeks) infants admitted to NICU at study facility within 24 hours of birth for in-born infants and up to 48 hours for out-born**
  • Mother and infant alive during screening
  • Mother age 18+ years
  • Lives within catchment areas of the facility
  • Mother intends to stay in catchment area of the study facility for at least 3 months
  • At randomization: Infant receiving at least 60 mL/kg/day of human milk***

Exclusion criteria

  • Lives outside the defined catchment area
  • Congenital abnormalities or acquired conditions that interfere with feeding or placement of nasogastric/orogastric tube [cleft lip/palate, toxoplasmosis, other agents, rubella, cytomegalovirus, and herpes (TORCH), Trisomy 21, congenital cardiac defect, neural tube defect, gastrointestinal tract anomalies, hydrocephalus, NEC]
  • Severe birth asphyxia
  • Critically ill (i.e. not on enteral feeds)
  • Unknown date of birth and unknown gestational age

Treatment and study plan

Human Milk Fortifier

Dietary Supplement

Human milk fortifier added to expressed human milk (mother's own milk or pasteurized donor human milk) per feed per manufacturer's instructions for a minimum of 21 days (in-facility provision only)

  • Clinical feeding guideline including targets for initiation and advancement of breast milk feeding
  • Provision of guideline-driven standard of care [facility-based lactation support/feeding counseling + KMC + WASH package (referred to as facility-based FSP+) and breast pumps]

Other names: Volume targets, Guideline-driven standard of care

Volume targets

Other
  • Clinical feeding guideline including targets for initiation and advancement of breast milk feeding
  • Provision of guideline-driven standard of care [facility-based lactation support/feeding counseling + KMC + WASH package (referred to as facility-based FSP+) and breast pumps]

Other names: Guideline driven standard of care

Primary outcomes

  1. Length-for-age Z score (LAZ)

    Time frame: 3 Months

    Mean LAZ (SD, range) measured at birth, 2 weeks, 4 weeks and 3 months of age

Secondary outcomes

  1. Length of Stay

    Time frame: From date of randomization until the date of facility discharge or date of death from any cause, whichever came first, assessed up to 3 months of age.

    Mean (SD) number of days admitted in the study facility from randomization to facility discharge

  2. Feeding intolerance

    Time frame: From randomization to facility discharge, assessed up to 3 months of age

    % infants identified with feeding intolerance

  3. Weight growth velocity

    Time frame: From randomization to facility discharge, assessed up to 3 months of age

    % infants attaining 15 g/kg/day

  4. Length gain

    Time frame: From randomization to facility discharge, assessed up to 3 months of age.

    Mean (SD) change in length (mm/week)

  5. Head circumference gain

    Time frame: From randomization to facility discharge, assessed up to 3 months of age

    Mean (SD) change in head circumference (mm per week)

  6. Necrotizing enterocolitis (NEC)

    Time frame: From randomization to facility discharge, assessed up to 3 months of age.

    % infants diagnosed with NEC

  7. Sepsis/possible serious bacterial infection (PSBI)

    Time frame: From randomization to facility discharge, assessed up to 3 months of age

    % diagnosed with sepsis or possible serious bacterial infection (PSBI)

  8. Infant mortality

    Time frame: From randomization to 3 months of age

    % infants died

  9. Birthweight regain

    Time frame: 2 weeks of age

    % infants who regain birthweight by 2 weeks of age

  10. Mean weight growth velocity (4 weeks)

    Time frame: From randomization to 4 weeks of age

    Mean (SD) change in weight (growth) at 4 weeks of age

  11. Neonatal mortality (4 weeks)

    Time frame: From randomization to 4 weeks of age

    % of neonates who died up to 4 weeks of age

  12. Sepsis/possible serious bacterial infection (PSBI, 4 weeks)

    Time frame: From randomization to 4 weeks of age

    % of infants diagnosed with sepsis/PSBI up to 4 weeks of age

  13. Mean weight growth velocity

    Time frame: From randomization to facility discharge, assessed up to 3 months of age.

    Mean change in infant weight (growth) calculated in grams/kilogram/day (g/kg/day)

  14. Weight-for-age Z score (WAZ)

    Time frame: 3 months of age

    Mean (SD) WAZ at 3 months of age

  15. Weight-for-length Z score (WLZ)

    Time frame: 3 months of age

    Mean (SD) weight-for-length Z score (WLZ) at 3 months of age

  16. Head circumference-for-age Z score (HcAZ)

    Time frame: 3 months of age

    Mean (SD) HcAZ

  17. Change in WAZ

    Time frame: From randomization to 3 months of age

    Change in WAZ from randomization to 3 months of age

  18. Change in LAZ

    Time frame: From randomization to 3 months of age

    Change in LAZ from randomization to 3 months of age

Study contacts

Contact information is provided by the study sponsor or research team.

Ilana Dzuba, MHS

CONTACT

[email protected]

617-384-6555

Linda Vesel, PhD, MPH

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Harvard School of Public Health (HSPH)

Other

Collaborators

  • Boston Children's Hospital
  • Brigham and Women's Hospital
  • Emory University
  • Jawaharlal Nehru Medical College
  • Muhimbili University of Health and Allied Sciences
  • PATH
  • University of North Carolina

Registry information

Official study title

Low Birthweight and Preterm Infant Feeding Trial and Supportive Care Package (LIFT-UP): Randomized Controlled Trial of In-facility Fortification of Human Milk in India

Acronym: LIFT-UP RCT

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jan 9, 2025
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.